

## / THE GLOBAL PROSTATE CANCER SYMPTOMS SURVEY /

### / OVERVIEW /

In early 2015, eight leading patient advocacy groups formed the International Prostate Cancer Coalition (IPCC) with the support of Bayer to commission the International Prostate Cancer Symptoms Survey, which examined the perspectives of men with advancing prostate cancer and their caregivers\*† on the disease and its symptoms.<sup>1</sup>

### / SYMPTOMS ARE A WARNING SIGN /

As the second most common cancer among men in the US<sup>2</sup>, prostate cancer is frequently discussed in doctors' offices, in the home and in the media. But these conversations are largely focused on diagnosis and early-stage treatment and may be missing an important element: the topic of advancing disease.

Symptoms may serve as a warning that prostate cancer is progressing, but research and feedback from patients indicate that men may not recognize symptoms related to their advanced prostate cancer – and even if they do, they don't always act on them.<sup>1,2,3</sup> The IPCC's International Prostate Cancer Symptoms Survey aimed to bridge the gap between symptom recognition and doctor/patient discussions, so men know when to speak up and take action on their advancing disease.<sup>1</sup>

#### ABOUT ADVANCING PROSTATE CANCER:

- In the US, prostate cancer is the second leading cause of cancer death in men, as approximately one in 38 will die from the disease.<sup>2</sup>
- Signs of advancing prostate cancer can include problems passing urine or the need to urinate more often, blood in the urine, erectile dysfunction, weakness or numbness in the legs or feet, loss of bladder or bowel control and tiredness that interrupts daily activities.<sup>1,2,4</sup>
- Difficulty walking or climbing stairs, unexplained pain in the hips, back/spine or chest/ribs, troubled sleep and taking pain relievers daily can also be signs of advancing prostate cancer that can have a major impact on daily life.<sup>1,2,4</sup>
- One in 20 men will have advanced disease when first diagnosed, and approximately 90 percent of men with advanced prostate cancer will have cancer that spreads to the bones, impacting survival and quality of life.<sup>5,6,7,8</sup>
- The stage of prostate cancer is one of the most important factors in determining treatment options and the outlook for recovery.<sup>2</sup>

### / THE IPCC /

The IPCC, led by US advocacy organization CancerCare, aims to raise awareness of the symptoms of advancing prostate cancer so that men and their loved ones know how and when to speak up and take action.

The IPCC has been integral in the development, recruitment, analysis and dissemination of the survey results. Medical experts have also contributed to this initiative, including renowned oncologists, urologists and nurse practitioners from around the globe who interact with patients regularly.



### SNAPSHOT: WHO WE'VE HEARD FROM<sup>1</sup>

Independent research company Harris Poll conducted the International Prostate Cancer Symptoms Survey online and by telephone across the globe. Questions ranged from understanding how long men have been living with the disease, to the symptoms of their prostate cancer, to the impact of prostate cancer on daily life.

The survey was conducted online and by phone by Harris Poll among a total of 927 men with advanced prostate cancer (410 in the US) and 400 adults who care for someone with prostate cancer (95 in the US) between February 12 and October 27, 2015.

US patients who participated in the survey had been living with advanced prostate cancer for an average of nine years.

More than half of US patients who participated in the survey (53 percent) reported they have prostate cancer that has already spread to the bones.



#### DISCLOSURES:

- The International Prostate Cancer Symptoms Survey was conducted online and by telephone in the United States by Harris Poll on behalf of Bayer between February 12 and October 27, 2015, among men with metastatic prostate cancer (N=927; 410 in the US) and adults who care for someone with metastatic prostate cancer (N=400; 95<sup>†</sup> in the US). Total sample data are not weighted and therefore representative only of the individuals interviewed.

\*Caregivers refers to adults who care for someone with advanced prostate cancer.

<sup>†</sup>Small base (n<100). Results should be interpreted as directional in nature.

For more information on the US results of the Prostate Cancer Symptoms Survey, visit [MenWhoSpeakUp.com](http://MenWhoSpeakUp.com).

#### REFERENCES:

1. Prostate Cancer Symptoms Survey: U.S. Results, 2015.
2. American Cancer Society. Prostate cancer. Available at: <http://www.cancer.org/acs/groups/cid/documents/webcontent/003134-pdf.pdf>. Accessed March 7, 2016.
3. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association 2015. Available at: <https://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdf>. Accessed March 7, 2016.
4. National Cancer Institute. Prostate cancer treatment-patient version (PDQ®). Available at: <http://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq#section/all>. Accessed March 7, 2016.
5. National Cancer Institute. SEER stat fact sheets: Prostate cancer. Available at: <http://seer.cancer.gov/statfacts/html/prost.html>. Accessed March 7, 2016.
6. Park JC, Eisenberger MA. Advances in the treatment of metastatic prostate cancer. *Mayo Clin Proc.* 2015;90(12):1719-1733.
7. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. *Int J Cancer.* 2011;128(11):2545-2561.
8. Goh P, Harris K, Napolskikh J, et al. New multidisciplinary prostate bone metastases clinic: first of its kind in Canada. *Curr Oncol.* 2007;14(1):9-12.

© 2019 Bayer. All rights reserved.

BAYER® and the Bayer Cross® are registered trademarks of Bayer. All other trademarks are property of their respective owners. These trademark owners are not affiliated with Bayer and do not sponsor or endorse Bayer.

THE INTERNATIONAL  
PROSTATE CANCER  
COALITION



CANCERcare®



grupo español de  
pacientes de cáncer

